Neuroprotekcija u Parkinsonovoj bolesti

master's thesis

• Title (english): Neuroprotection in Parkinson's disease
• Author: Ena Pejković
• Mentor: Srđana Telarović (mentor)
• Committee member: Zdravka Poljaković (predsjednik povjerenstva)
• Committee member: Mario Habek (član povjerenstva)
• Committee member: Srđana Telarović (član povjerenstva)
• Granter: University of Zagreb; School of Medicine; (Department of Neurology); Zagreb
• Defense date and country: 2014-07-15, Croatia
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Neurology

Abstract

Parkinsonova bolest (PB) je kronična progresivna neurodegenerativna bolest koja oštećuje živčane stanice u nigrostrijatalnim dopaminergičkim područjima mozga. Javlja se u približno 1% populacije u dobi iznad 60 godina. Smatra se da je etiologija multifaktorska i da bolest nastaje interakcijom genskih i okolišnih čimbenika, dok se velika uloga pripisuje i djelovanju slobodnih radikala, mitohondrijskoj disfunkciji te mehanizmu oksidativnog stresa. Možda je najvažniji izazov za liječenje u PB mehanizam kojim će se odgoditi ili spriječiti daljnji gubitak dopaminergičkih i nedopaminergičkih neurona. U radu se navode najvažniji rezultati dosadašnjih istraživanja, odnosno sistemski pregled predkliničkih podatka o neuroprotektivnim agentima za PB. Levodopa se trenutno smatra zlatnim standardom neuroprotektivnog djelovanja na PB, što su studije i pokazale. Za inhibitore monoamino oksidaze B (MAO-B), agoniste dopamina, antagoniste N-metil-D-aspartat (NMDA) receptora, blokatore kalcijevih kanala i nikotin postoje jednoglasni pozitivni stavovi o utjecaju na razvoj PB. Podaci upućuju da su kofein i melatonin jaki neuroprotektanti dok za acetilsalicilnu kiselinu, kurkumin, koenzim Q10 i zeleni čaj još ne postoje jednoglasni pouzdani podaci. Različiti rezultati i stavovi ove problematike upućuju na potrebu daljnjih istraživanja s jasno definiranim kriterijima i ciljevima u svrhu dobivanja pouzdanih podataka. Samo takvi podaci mogu biti polazište za uključivanje u kliničku praksu temeljenu na dokazima te mogu uvelike pridonijeti razvitku novih i učinkovitih načina liječenja PB.

Abstract (english)

Parkinson's disease (PD) is a chronic progressive neurodegenerative disease that damages neurons in nigrostriatal dopaminergic brain regions. It occurs in approximately 1% of the population aged over 60 years. It is believed that the etiology is multifactorial and results from interaction of genetic and environmental factors, while a large part is attributed to the action of free radicals, mitochondrial dysfunction and oxidative stress mechanism. Perhaps the most important challenge for the treatment of PD is mechanism how to delay or prevent further loss of dopaminergic and nondopaminergic neurons. This review presents the most important results of previous studies or systematic review of preclinical data on neuroprotective agents for PD. Levodopa is currently considered the gold standard for neuroprotective effects in PD, as the study showed. There are unanimously positive attitudes about the impact on the development of PD for inhibitors of monoamine oxidase B (MAO-B), dopamine agonists, N-methyl-D-aspartate (NMDA) receptor antagonists, calcium channel blockers and nicotine. The data suggest that caffeine and melatonin are potent neuroprotectant and there are still no unanimous reliable data for acetylsalicylic acid, curcumin, coenzyme Q10 and green tea. Different results and attitudes of these issues point to the need for further research with clearly defined criteria and objectives in order to obtain reliable data. Only such data can be a starting point for inclusion in clinical practice based on evidence and can greatly contribute to the development of new and effective ways of treating PD.

• Keywords: Parkinsonova bolest; neurodegeneracija; neuroprotekcija
• Keywords (english): Parkinson's disease; neurodegeneration; neuroprotection
• Language: croatian
• URN:NBN: urn:nbn:hr:105:392321
• Study programme: Title: Medicine; Study programme type: university; Study level: integrated undergraduate and graduate; Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
• Type of resource: Text
• File origin: Born digital
• Access conditions: Open access
• Created on: 2015-10-26 13:05:41